A Medicare pilot program designed to expand access to obesity medications among seniors has collapsed after participating insurers declined to join, forcing the federal government to pursue an alternative coverage path outside the standard Medicare Part D drug benefit structure.

The program, called BALANCE, had been constructed around a negotiated arrangement between the Trump administration and two of the largest glucagon-like peptide-1 (GLP-1) drug manufacturers. Eli Lilly and Novo Nordisk agreed to sell their obesity treatments at $245 per month under the program, a price substantially below standard list prices, in exchange for expanded access through both Medicare and Medicaid. The federal government, for its part, committed that Medicare beneficiaries enrolled in the pilot would face out-of-pocket costs of no more than $50 per month. The framework appeared, at least structurally, to balance manufacturer concessions against meaningful patient affordability.

It didn’t hold.

The BALANCE pilot required Medicare Part D drug plans covering at least 80% of enrollees to agree to participate. Insurers declined. Their concern wasn’t difficult to understand: even at the negotiated manufacturer price, the volume of eligible seniors and the gap between that $245 monthly drug cost and the $50 patient copay created an exposure that plans assessed as financially untenable. The threshold was never met, and the pilot as originally designed cannot proceed.

The government’s pivot, covering these drugs outside of Part D, carries its own set of administrative and coverage questions that have not yet been fully resolved. What the arrangement signals, however, is that the administration doesn’t intend to abandon the access objective. The GLP-1 coverage problem for Medicare beneficiaries has been a persistent policy gap. The Centers for Medicare and Medicaid Services has historically excluded weight loss drugs from Part D coverage except where indicated for a comorbid condition such as type 2 diabetes or cardiovascular disease, which is why drugs like semaglutide reached many seniors only through the diabetes indication, not through an obesity label. BALANCE was meant to close that gap directly.

The collapse of the insurer participation threshold is a concrete setback. Tens of millions of Medicare beneficiaries carry diagnoses consistent with obesity, and the downstream cardiovascular burden in that population is well-documented. The SELECT trial, published in 2023, demonstrated that semaglutide reduced major adverse cardiovascular events (MACE) in patients with overweight or obesity and established cardiovascular disease, cutting the composite endpoint of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 20% relative to placebo. That data was central to the American College of Cardiology and American Heart Association’s updated guidance on GLP-1 agents in high-risk cardiovascular patients. Cardiologists treating elderly populations in Hawaii and across the country have watched access barriers slow the translation of that trial data into clinical practice.

Costs are the dominant friction. At retail prices well above $1,000 per month, these agents remain out of reach for most Medicare beneficiaries on fixed incomes. The $50 copay structure under BALANCE was designed specifically to address that barrier. Its failure to launch means those patients are back to negotiating access through manufacturer assistance programs, prior authorization processes tied to cardiovascular or metabolic indications, or simply going without.

Meanwhile, in the commercial market, access is expanding through a different channel entirely. Amazon has launched a program through its One Medical primary care arm that gives patients access to GLP-1 treatments, including Novo Nordisk’s Wegovy and Eli Lilly’s Foundayo weight loss pills, starting at $25 per month with insurance coverage and $149 per month for cash-pay options. The One Medical program is structured around ongoing clinical supervision rather than a single prescribing encounter, with clinicians monitoring patient progress, adjusting treatment regimens, and addressing related health conditions over time. That model contrasts with the episodic prescribing that characterized early telehealth-based weight loss offerings.

The cash-pay pricing sits in line with what competitors charge. Programs from Hims and Hers Health, Walgreens, and Weight Watchers have established similar pricing tiers for starter doses. But Amazon’s entry into supervised GLP-1 management carries scale implications that single-site or telehealth-only competitors can’t match, and markets responded accordingly. Shares of Hims and Hers closed down 4% at $29.76 on Tuesday. Weight Watchers fell 8.8%. Even Novo Nordisk, whose product is central to Amazon’s new offering, declined 2.6%, likely reflecting investor concern about pricing pressure as distribution channels multiply.

Amazon’s move is significant for what it suggests about where GLP-1 access is heading in the commercial market: toward integrated, longitudinally supervised care delivered through primary care infrastructure at consumer-level price points. Whether that model translates to anything useful for Medicare beneficiaries is a separate question. One Medical’s patient base skews working-age and commercially insured, and STAT News reported the insurer participation failure and the Amazon launch in parallel, a juxtaposition that illustrates how differently the commercial and public insurance markets are moving on GLP-1 access.

The clinical stakes in older populations are not trivial.

Obesity in patients over 65 is associated with accelerated progression of heart failure with preserved ejection fraction (HFpEF), a condition for which pharmacologic options have historically been limited. The STEP-HFpEF trial showed that semaglutide produced marked improvements in the Kansas City Cardiomyopathy Questionnaire (KCCQ) score and reduced body weight by 13.3% compared to 2.6% with placebo, with a between-group difference reaching statistical significance at a p-value below 0.001. For the cardiologist managing a Medicare patient with HFpEF and obesity, that trial data creates a clear treatment rationale. The access infrastructure just hasn’t caught up.

Part D plans weren’t wrong to worry about financial exposure. The math is real.

If even 5% of the roughly 67 million Medicare beneficiaries qualify for GLP-1 therapy under an obesity indication, the drug spend at $245 per month per enrollee runs into the tens of billions annually. The insurer actuarial concern isn’t manufactured. But the policy question is whether a financing model that leaves that population without access to a drug class with Class I-level cardiovascular outcome data is clinically or ethically sustainable. The ACC/AHA 2023 heart failure guidelines and the 2019 cardiovascular risk reduction guidance both moved GLP-1 receptor agonists into high-recommendation territory for specific indications. Medicare coverage policy has not kept pace.

Hawaii’s patient population adds a dimension that national coverage debates often miss. The state has a substantially higher proportion of Asian and Pacific Islander residents than the national average, groups in whom visceral adiposity and cardiometabolic risk manifest at lower body mass index (BMI) thresholds than standard obesity criteria reflect. The BMI cutoffs embedded in most GLP-1 coverage criteria were derived from predominantly white study populations and don’t account for the elevated metabolic risk seen in Asian patients at BMIs of 23 to 27.5, a range the World Health Organization flagged in its 2004 guidance. Physicians at institutions across Honolulu have raised this issue in clinical settings for years, arguing that standard eligibility thresholds systematically deny access to higher-risk patients who don’t fit Western-derived BMI categories.

The collapse of BALANCE doesn’t close the policy conversation. The administration’s decision to seek an alternative coverage mechanism outside Part D suggests the objective of expanding access hasn’t been abandoned, only rerouted. What that rerouting looks like in practice, which beneficiaries it reaches, at what cost, and through what administrative structure, will determine whether the pivot produces anything clinically meaningful or whether it amounts to a bureaucratic workaround that leaves the access gap largely intact. For cardiologists managing elderly patients with obesity-related cardiovascular disease in Hawaii and across the country, the outcome of that rerouting carries direct consequences for what they can prescribe, and for what their patients can afford to fill.